论文部分内容阅读
目的观察升清和健脾理气药物对饮食诱导肥胖(DIO)大鼠肥胖程度及对脂联素和炎症因子的影响。方法 Wistar大鼠120只,10只作为空白对照组,给予基础饲料,其余110只给予高脂高营养饲料17周,按照体重,得到DIO大鼠40只和肥胖抵抗(DIO-R)大鼠10只,将DIO大鼠又分为DIO模型组、西布曲明组、健脾理气组和升清组,每组10只,分别以生理盐水(2 m L/d)、西布曲明1.6 mg/(kg·d)、健脾理气药物3.2 g/(kg·d)、升清药物3.2 g/(kg·d)灌胃,空白对照组与DIO-R组予生理盐水(2 m L/d)灌胃。灌胃期间空白对照组予基础饲料,余5组继续高脂饲料。灌胃16周后,测量体重、身长,取腹腔内全部脂肪,测量肥胖程度及脂肪含量。取血测定胰岛素抵抗指数(IRI)、血糖、甘油三酯、胆固醇、肿瘤坏死因子(TNF-α)、脂联素。取脂肪匀浆测定TNF-α、脂联素。结果 DIO模型组比正常大鼠体重、体重指数、脂肪系数、胆固醇、IRI明显升高(P<0.05,P<0.01);血清和脂肪中脂联素均下降(P<0.05),TNF-α均升高(P<0.05,P<0.01)。与DIO模型组比较,DIO-R组体重、体重指数、脂肪系数、IRI均降低(P<0.05,P<0.01);血清和脂肪中脂联素升高(P<0.01),TNF-α降低(P<0.05,P<0.01)。健脾理气药物可降低脂肪匀浆中TNF-α水平(P<0.05);升清药物可以升高血清及脂肪匀浆中脂联素水平,降低TNF-α(P<0.05,P<0.01)。结论升清药物能抑制高脂饲料诱导的肥胖和胰岛素抵抗,其机制与促进脂联素分泌,降低TNF-α水平有关。“脾不升清”可能是肥胖的病机关键之一。
Objective To observe the effect of Shengqing and Jianpi Liqi on obesity, adiponectin and inflammatory factors in diet-induced obesity (DIO) rats. Methods One hundred and twenty Wistar rats were used as blank control group, the basal diet was given, and the remaining 110 were given high-fat and high-nutrition diets for 17 weeks. According to body weight, 40 DIO rats and 10 obesity resistant rats (DIO-R) Only DIO rats were divided into DIO model group, sibutramine group, Jianpi Liqi group and Shengqing group, with 10 rats in each group. Normal saline (2 m L / d), sibutramine 1.6 kg / d, 3.2 g / (kg · d) for spleen and qi, and 3.2 g / (kg · d) for RQ). The rats in control group and DIO-R group were given saline / d) Gavage. Gavage during the control group to the basic diet, the remaining 5 groups continue to high-fat diet. After 16 weeks of gavage, body weight, body length, total fat in the abdominal cavity, fatness and fat content were measured. Blood samples were collected for determination of insulin resistance index (IRI), blood glucose, triglycerides, cholesterol, tumor necrosis factor (TNF-α) and adiponectin. Take fat homogenate determination of TNF-α, adiponectin. Results The body weight, body mass index, fat coefficient, cholesterol and IRI in DIO model group were significantly higher than those in normal rats (P <0.05, P <0.01) (P <0.05, P <0.01). Compared with DIO model group, the body weight, body mass index, fat index and IRI in DIO-R group were significantly lower (P <0.05, P <0.01); adiponectin in serum and adipose tissue was increased (P <0.05, P <0.01). (P <0.05). Shengqijian can increase adiponectin level in serum and fat homogenate and decrease TNF-α (P <0.05, P <0.01) . Conclusions Shengqing drug can inhibit the obesity and insulin resistance induced by high-fat diet, the mechanism of which is related to promoting the secretion of adiponectin and decreasing the level of TNF-α. “Spleen does not ascend” may be one of the keys to the pathogenesis of obesity.